---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Heterogeneity of treatment effect"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Heterogeneity of treatment effect. Topics: Distribution of pathophysiologic traits in OSA; Endotypic predictors of complete response to atomoxetine plus oxybutynin, AHI with 3% desaturation or arousal hypopnea rule; MARIPOSA post hoc subgroups, AHI with 4% desaturation hypopnea rule; SynAIRgy prespecified subgroups by sex, severity, and BMI, AHI with 4% desaturation hypopnea rule; 6 further topics. 10 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### Distribution of pathophysiologic traits in OSA

> “One or more nonanatomic pathophysiologic traits are present in 69% of patients with OSA.”

Source: [Eckert et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3826282/)

<a id="topic-2.2.2.3-2"></a>

### Endotypic predictors of complete response to atomoxetine plus oxybutynin, AHI with 3% desaturation or arousal hypopnea rule

> “Hypopneas were defined as a reduction in flow ≥ 30% from baseline, lasting at least 10 s, and associated with an arousal from sleep or an oxyhemoglobin desaturation ≥ 3%.”
> “Figure 5 shows individual data: eight of 14 subjects had a complete response to ato-oxy (50% reduction in AHI from placebo and AHI on drug < 10 events/h). These data show that patients with an AHI on placebo < 40 events/h, Fhypopneas > 65%, and Vpassive > 55% were associated with the best likelihood of complete response on ato-oxy.”
> “Patients with relatively lower AHI and less severe upper airway collapsibility had the best chance for OSA resolution with ato-oxy.”

Source: [Taranto-Montemurro et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7268440/)

<a id="topic-2.2.2.3-3"></a>

### MARIPOSA post hoc subgroups, AHI with 4% desaturation hypopnea rule

> “Post hoc analyses showed no statistically significant differences in AHI4 reduction between subgroups based on age, sex, obesity, or baseline OSA severity (Tables E4–E7 in the online supplement). However, a higher proportion of participants with a baseline AHI4 in the mild to moderate range (AHI4 10–30 events/h) experienced a resolution of OSA (defined as AHI4 <10 events/h) compared with those with a baseline AHI4 in the severe range (AHI4 ⩾30; 52.2% vs. 7%; P = 0.004; Figure E2 in the online supplement).”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-2.2.2.3-4"></a>

### SynAIRgy prespecified subgroups by sex, severity, and BMI, AHI with 4% desaturation hypopnea rule

> “Similar improvements in AHI at week 26 were observed among participants in the AD109 arm across various subgroups including sex, baseline OSA severity categories (mild, moderate, and severe), and BMI classes (Figure S3). AD109 treatment effects on AHI were consistent across estimands, with larger effect sizes observed in the supportive on-treatment estimand in participants who tolerated treatment (Table 3, Figure 2D and E, Figure S3).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-2.2.2.3-5"></a>

### Pooled phase 3 analysis: subgroups by baseline severity under both estimands and by BMI under the on-treatment estimand, AHI with 4% desaturation hypopnea rule

> “An analysis of sub-groups based on baseline OSA severity showed similar clinical response in participants with mild, moderate, and severe OSA at baseline (Figure 20). In each subgroup and for both estimands, more participants achieved AHI reductions at each threshold with AD109 compared to placebo (Figure 21).”
> “A similar analysis was conducted using sub-groups based on baseline BMI, including those without obesity (BMI<30), those with mild obesity (BMI 30-35), and those with more severe obesity (BMI>35). As shown in Figure 22, more participants achieved AHI reductions at each threshold with AD109 compared to placebo.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.2.3-6"></a>

### Pooled phase 3 analysis: patient-reported outcomes by baseline sleepiness, treatment policy and on-treatment estimands

> “Moreover, in a prespecified subgroup of participants with ESS ≥ 10, representing patients with greater baseline sleepiness (approximately two standard deviations above the mean general population value of about six), AD109 demonstrated a statistically significant improvement in PROMIS Fatigue and PROMIS Sleep Impairment compared with placebo in both the treatment-policy (p<0.05) and on-treatment (p<0.01) estimands.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.2.3-7"></a>

### Variability in response and symptomatic benefit confined to subgroups in an editorial on SynAIRgy

> “However, among participants with greater baseline symptom burden of fatigue and sleepiness, improvements in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue scores were observed, suggesting that symptomatic benefit may be confined to selected subgroups.”
> “In addition, variability in treatment response highlights the need for strategies to identify patients most likely to benefit.”

Source: [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

<a id="topic-2.2.2.3-8"></a>

### Atomoxetine plus oxybutynin in Japanese participants: responders within a null trial

> “The values of AHI, nadir SpO2 , 3% oxygen desaturation index (ODI), 4% ODI, and SpO2 drop time of <90% did not significantly differ between patients receiving ATO-OXY administration and no medication.”
> “However, the subanalysis demonstrated an obvious decrease in AHI in five responder patients.”
> “Future studies for identifying treatment response group characteristics are warranted.”

Source: [Kinouchi et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36184258/)

<a id="topic-2.2.2.3-9"></a>

### Atomoxetine plus oxybutynin for 30 days in predominantly severe OSA, AHI with 3% and 4% desaturation hypopnea rules

> “Thirty-nine people with predominantly severe OSA received 80/5 mg ato-oxy, 40/5 mg ato-oxy, 40/2.5 mg ato-oxy, or placebo nightly for 30 days in a double-blind, randomized, parallel design.”
> “Apnea-hypopnea index (AHI) with 4% oxygen desaturation and hypoxic burden decreased by ∼50% with 80/5 mg ato-oxy from baseline but not versus placebo (e.g., AHI with 3% oxygen desaturation and AHI with 4% oxygen desaturation difference at Night 30 was -8.2 [95% confidence interval, -22.5 to 6.2] and -8.5 [95% confidence interval, -18.3 to 1.3] events/h, respectively).”

Source: [Aishah et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36538809/)

<a id="topic-2.2.2.3-10"></a>

### Adherence as a modifier of cardiovascular benefit with positive airway pressure

> “The main outcome was defined as the first MACCE, which was similar for the CPAP and no CPAP groups (hazard ratio, 1.01 [95% CI, 0.87-1.17]). However, an on-treatment analysis by marginal structural model revealed a reduced risk of MACCEs associated with good adherence to CPAP (hazard ratio, 0.69 [95% CI, 0.52-0.92]).”

Source: [Sánchez-de-la-Torre et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10548300/)

Additional sources: [Messineo et al. (2023)](https://publications.ersnet.org/lookup/doi/10.1183/13993003.congress-2023.PA3594); [Gell et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41932835/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
